Targeting intracellular oncoproteins with antibody therapy or vaccination

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Antibody therapies offer improved cancer treatment specificity and efficacy compared to chemotherapy.
• Traditional antibody therapies target extracellular or secreted proteins, limiting treatment options for intracellular oncogenic proteins.
• Many crucial cancer-driving proteins are located intracellularly, posing a challenge for existing antibody-based treatments.

Purpose of the Study:

• To investigate the potential of antibody therapy and vaccination against intracellular oncoproteins.
• To demonstrate the feasibility of targeting intracellular proteins for cancer treatment.

Main Methods:

• Selected three intracellular proteins: PRL-3 (phosphatase of regenerating liver 3), EGFP (enhanced green fluorescent protein), and mT (polyomavirus middle T oncoprotein) as immunogens.
• Utilized exogenous antibodies and antigen-induced host antibodies (vaccination) to target these intracellular proteins.
• Evaluated anticancer activity in various tumor models, including C57BL/6 mice and MMTV-PymT transgenic mice.

Main Results:

• Demonstrated significant inhibition of tumors expressing intracellular PRL-3, EGFP, and mT.
• Confirmed anticancer effects using both direct antibody administration and vaccination-induced immune responses.
• Reproducibly observed these therapeutic effects in hundreds of tumor-bearing mice.

Conclusions:

• Antibody-based immunotherapies can effectively target intracellular oncoproteins, expanding treatment possibilities.
• This approach holds promise for developing novel cancer therapies against previously inaccessible intracellular targets.
• The findings support the potential of targeting intracellular proteins for both antibody therapy and cancer vaccination.